Jacobio Pharmaceuticals Group Co (HKSE:01167) ROCE % : -28.45% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Jacobio Pharmaceuticals Group Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jacobio Pharmaceuticals Group Co's annualized ROCE % for the quarter that ended in Dec. 2023 was -28.45%.

Jacobio Pharmaceuticals Group Co ROCE % Historical Data

The historical data trend for Jacobio Pharmaceuticals Group Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jacobio Pharmaceuticals Group Co ROCE % Chart

Jacobio Pharmaceuticals Group Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-108.45

-144.64

-17.80

-22.97

-25.95

Jacobio Pharmaceuticals Group Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial						-19.25	-15.80	-32.12	-22.88	-28.45

Jacobio Pharmaceuticals Group Co ROCE % Calculation

Jacobio Pharmaceuticals Group Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-383.705	/	( ( (1758.431 - 174.041)	+	(1597.443 - 224.367) )	/ 2 )
	=	-383.705	/	( (1584.39	+	1373.076)	/ 2 )
	=	-383.705	/	1478.733
	=	-25.95 %

Jacobio Pharmaceuticals Group Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-411.91	/	( ( (1744.582 - 221.899)	+	(1597.443 - 224.367) )	/ 2 )
	=	-411.91	/	( ( 1522.683	+	1373.076 )	/ 2 )
	=	-411.91	/	1447.8795
	=	-28.45 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Jacobio Pharmaceuticals Group Co (HKSE:01167) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Jacobio Pharmaceuticals Group Co ROCE % Related Terms

Thank you for viewing the detailed overview of Jacobio Pharmaceuticals Group Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Jacobio Pharmaceuticals Group Co (HKSE:01167) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

JBPHF:USA

Address

No. 88, Kechuang 6th Street, Building F2, Beijing Economic-Technological Development Area, Beijing, CHN

Website

http://www.jacobiopharma.com

Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology therapies.

Executives

Shen Zhu	2501 Other
Treasure Partner International Limited	2501 Other
Ultimate Estate Limited	2201 Interest of corporation controlled by you
Wang Yinxiang	2501 Other
Wang Xiaojie	2307 Founder of a discretionary trust who can infl
Hu Yunyan	2501 Other
Yakovpharma Ltd	2501 Other
Willgenpharma Ltd	2501 Other
Risepharma Ltd	2101 Beneficial owner
Johwpharma Ltd	2501 Other
Hmed Ltd	2501 Other
Gloryviewpharma Ltd	2501 Other
Honourpharma Ltd	2501 Other
Blesspharma Ltd	2501 Other
Hillhouse Investment Management, Ltd.	2102 Investment manager

Jacobio Pharmaceuticals Group Co (HKSE:01167) Headlines

No Headlines